Page last updated: 2024-11-07

pregnanetriol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Pregnanetriol is a steroid hormone metabolite that is produced in the adrenal glands. It is a derivative of progesterone, and its synthesis involves the reduction of the 20-keto group of progesterone. Pregnanetriol is a relatively weak androgen, and its effects are primarily mediated through the androgen receptor. The compound is important for research because it is a marker for 21-hydroxylase deficiency, an autosomal recessive genetic disorder that affects the production of cortisol and aldosterone. Pregnanetriol levels are elevated in individuals with this disorder. Pregnanetriol is also studied for its potential role in other conditions, such as polycystic ovary syndrome (PCOS) and endometriosis. The compound is found in increased amounts in the urine of individuals with these conditions. Research on pregnanetriol is ongoing, and the compound may play a role in the development of new diagnostic and therapeutic strategies for these conditions.'

Pregnanetriol: A metabolite of 17-ALPHA-HYDROXYPROGESTERONE, normally produced in small quantities by the GONADS and the ADRENAL GLANDS, found in URINE. An elevated urinary pregnanetriol is associated with CONGENITAL ADRENAL HYPERPLASIA with a deficiency of STEROID 21-HYDROXYLASE. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID101967
CHEMBL ID1878246
CHEBI ID34464
SCHEMBL ID607860
MeSH IDM0017508

Synonyms (38)

Synonym
pregnanetriol
pregnantriol
smr000127415
MLS000517249
nsc-52760
nsc52760
1098-45-9
5beta-pregnane-3alpha,17alpha,20alpha-triol
13933-75-0
(3r,5r,8r,9s,10s,13s,14s,17r)-17-[(1s)-1-hydroxyethyl]-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthrene-3,17-diol
NCGC00247055-01
5-alpha,pregnane-3-alpha,17-alpha,20-beta-triol
nsc 52760
pregnane-3,17,20-triol, (3alpha,5beta,20s)-
unii-43822s61tb
43822s61tb ,
5-beta-pregnane-3-alpha,17-alpha,20-alpha-triol
einecs 214-148-0
HMS2269L20
SCHEMBL607860
pregnane-3,17,20-triol, (3.alpha.,5.beta.,20s)-
3.alpha.,17.alpha.,20.alpha.-trihydroxy-5.beta.-pregnane
5.beta.-pregnane-3.alpha.,17,20.alpha.-triol
CHEBI:34464 ,
CHEMBL1878246
5-pregnane-3,17,20-triol
SCPADBBISMMJAW-UHHUKTEYSA-N
(1s,2s,5r,7r,10r,11s,14r,15s)-14-(1-hydroxyethyl)-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecane-5,14-diol
J-002337
AKOS027381615
DTXSID00911364
(3r,5s,8r,9s,10s,13s,14s,17r)-17-((s)-1-hydroxyethyl)-10,13-dimethylhexadecahydro-1h-cyclopenta[a]phenanthrene-3,17-diol
Q7239897
(3alpha,5beta,20s)-pregnane-3,17,20-triol
(3r,8r,9s,10s,13s,14s,17r)-17-((s)-1-hydroxyethyl)-10,13-dimethylhexadecahydro-1h-cyclopenta[a]phenanthrene-3,17-diol
5 beta -pregnane-3 alpha ,17 alpha ,20 alpha -triol
3alpha,17alpha,20alpha-trihydroxy-5beta-pregnane
(1r,3as,3br,5ar,7r,9as,9bs,11as)-1-[(1s)-1-hydroxyethyl]-9a,11a-dimethyl-hexadecahydro-1h-cyclopenta[a]phenanthrene-1,7-diol

Research Excerpts

Actions

ExcerptReferenceRelevance
"Pregnanetriol excretion was lower (P less than .005) in RA patients than control subjects only during ACTH-stimulation."( Low adrenal androgenic-anabolic steroids in women with rheumatoid arthritis (RA): gas-liquid chromatographic studies of RA patients and matched normal control women indicating decreased 11-deoxy-17-ketosteroid excretion.
Jefferson, WE; Josipović, DB; Masi, AT, 1984
)
0.99

Dosage Studied

ExcerptRelevanceReference
" Some patients showed isolated 17OH-progesterone elevations (usually early morning), a situation which requires only revision of the cortisol dosage schedule without an increase in total dosage."( The application of a serum 17OH-progesterone radioimmunoassay to the diagnosis and management of congenital adrenal hyperplasia.
Hughes, IA; Winter, JS, 1976
)
0.26
" Repeated careful clinical examination and assessment of changes in growth velocity and skeletal maturation seem to be the best criteria on which to base dosage of corticosteroids used for therapy."( Urinary and serum steroid concentrations in the management of congenital adrenal hyperplasia. Lack of physiologic correlations.
Hendricks, SA; Kaplan, SA; Lavin, N; Lippe, BM; Mayes, DM, 1982
)
0.26
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
corticosteroid hormoneAny of a class of steroid hormones that are produced in the adrenal cortex.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
TDP1 proteinHomo sapiens (human)Potency23.72460.000811.382244.6684AID686978; AID686979
gemininHomo sapiens (human)Potency29.09290.004611.374133.4983AID624297
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (11)

Assay IDTitleYearJournalArticle
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (679)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990623 (91.75)18.7374
1990's17 (2.50)18.2507
2000's18 (2.65)29.6817
2010's18 (2.65)24.3611
2020's3 (0.44)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 29.14

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index29.14 (24.57)
Research Supply Index6.63 (2.92)
Research Growth Index4.31 (4.65)
Search Engine Demand Index39.83 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (29.14)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials18 (2.44%)5.53%
Reviews16 (2.17%)6.00%
Case Studies49 (6.65%)4.05%
Observational0 (0.00%)0.25%
Other654 (88.74%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]